WELLNESS
Physician-supervised GLP-1 therapy (Tirzepatide & Semaglutide) for effective, sustainable weight loss.
Science-backed medication. Personalized support. Real, lasting results.
Struggling with weight loss despite diet and exercise? You’re not alone—and it’s not a lack of willpower. For many, biological factors make sustained weight loss incredibly difficult.
At Skinovatio Ohio, we offer physician-supervised GLP-1 therapy using two of the most advanced medications available: Tirzepatide and Semaglutide. These medications work with your body’s natural hormones to reduce appetite, control cravings, and support meaningful, sustainable weight loss.
Under the care of our medical team, we don’t just prescribe a medication—we create a comprehensive, personalized weight loss plan that includes nutritional guidance, ongoing monitoring, and lifestyle support.
GLP-1 stands for glucagon-like peptide-1—a hormone your body naturally releases after eating. GLP-1 medications mimic this hormone to help you lose weight through multiple pathways:
| Mechanism | How It Helps |
|---|---|
| Reduces Appetite | Signals your brain that you’re full, reducing hunger and cravings |
| Slows Digestion | Food moves more slowly through your stomach, keeping you feeling full longer |
| Stabilizes Blood Sugar | Stimulates insulin release when blood sugar rises, supporting fat loss |
| Reduces Cravings | Helps break the cycle of crash-and-crave dieting |
This combination allows you to achieve caloric restriction without the constant struggle that often follows traditional dieting approaches.
| Tirzepatide (Mounjaro® / Zepbound®) | Semaglutide (Wegovy®) |
|---|---|
| Dual GLP-1 + GIP receptor agonist | Single GLP-1 receptor agonist |
| Targets two natural appetite hormones | Targets one natural appetite hormone |
| Greater average weight loss | Significant weight loss |
| Potential for reduced GI side effects | Well-established safety profile |
| Average weight loss: 15–20% of body weight | Average weight loss: ~14% of body weight |
Tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP receptor activation enhances lipid oxidation and adipocyte remodeling, leading to more pronounced weight reduction.
In clinical trials, participants with obesity (without diabetes) treated with tirzepatide lost an average of 20.2% of their body weight at 72 weeks—the highest percentage weight loss of any medication available for obesity.
Semaglutide is a well-established GLP-1 receptor agonist with a strong safety profile. In clinical trials and real-world use, it has consistently demonstrated significant weight loss—approximately 14–15% of body weight on average.
Which is right for you? Our medical team will assess your health history, goals, and preferences to recommend the best option for your unique needs.
Your journey begins with a comprehensive medical evaluation. We review your health history, discuss your weight loss goals, and determine if GLP-1 therapy is appropriate for you. We also address any questions you may have about the medication, side effects, and the program.
If you’re a candidate, we create a personalized plan that includes:
Medication type and dosing schedule
Nutritional guidance
Lifestyle recommendations
Follow-up schedule
Both medications are started at a low dose and gradually increased to minimize side effects and allow your body to adjust.
| Phase | Semaglutide (Wegovy®) | Tirzepatide (Zepbound®) |
|---|---|---|
| Starting Dose | 0.25 mg once weekly | 2.5 mg once weekly |
| Titration | Increase every 4 weeks | Increase every 4 weeks |
| Maintenance Dose | 2.4 mg once weekly | 10–15 mg once weekly |
Regular follow-up appointments to track progress and adjust treatment
Nutritional guidance to maximize results and support long-term habits
Side effect management strategies to keep you comfortable
Ongoing medical supervision to ensure safety and effectiveness
You may be a candidate for GLP-1 therapy if you:
| Criterion | Details |
|---|---|
| BMI ≥ 30 | Classified as having obesity |
| BMI ≥ 27 with weight-related condition | Such as hypertension, dyslipidemia, or diabetes |
| Struggled with weight loss | Despite diet and exercise efforts |
| Committed to lifestyle changes | Medication works best with nutrition and activity support |
| No contraindications | Certain medical conditions may prevent use |
Important: GLP-1 medications are not appropriate for everyone. A thorough medical evaluation is required to ensure safety and suitability.
GLP-1 therapy offers benefits that extend beyond the scale:
| Benefit | Impact |
|---|---|
| Improved metabolic health | Better blood sugar control and insulin sensitivity |
| Reduced cardiovascular risk | Lower blood pressure and improved lipid profiles |
| Enhanced quality of life | Improved energy, sleep, and mental health |
| Sustainable results | Breaks the cycle of yo-yo dieting |
| Reduced obesity-related conditions | Lower risk of diabetes, hypertension, and other conditions |
Many patients report regaining control over their eating habits for the first time in years.
GLP-1 medications are generally well-tolerated, but side effects can occur.
Most side effects are mild to moderate and occur primarily during dose escalation:
| Side Effect | Management |
|---|---|
| Nausea | Start low, go slow; small, frequent meals |
| Diarrhea | Stay hydrated; avoid fatty foods |
| Vomiting | Contact your provider if persistent |
| Constipation | Increase fiber and water intake |
| Fatigue | Rest; usually resolves with time |
Discontinuation rates are low—in clinical trials, only 3–6% of participants stopped treatment due to side effects
Not recommended during pregnancy or breastfeeding
Inform your provider about all medications and medical conditions
Regular monitoring ensures safety and optimal dosing
| Reason | What It Means for You |
|---|---|
| Physician Supervision | All treatments are supervised by our Medical Director—not a generic online platform |
| Personalized Care | Every plan is customized to your unique health profile and goals |
| Comprehensive Support | Beyond medication, we provide nutritional guidance, monitoring, and lifestyle support |
| Evidence-Based Approach | We follow the latest clinical guidelines and research |
| Ongoing Monitoring | Regular follow-up ensures safety, effectiveness, and long-term success |
How much weight can I expect to lose?
In clinical trials, patients on tirzepatide lost an average of 15–20% of their body weight. Semaglutide patients lost approximately 14% on average. Individual results vary based on adherence, lifestyle, and other factors.
How quickly will I see results?
Most patients begin to see results within the first few weeks. Significant weight loss accumulates over several months as the dose is gradually increased.
Do I have to stay on the medication forever?
GLP-1 therapy is typically used as a long-term tool for weight management. Some patients may be able to reduce or transition off medication with sustained lifestyle changes, but many benefit from ongoing treatment to maintain results.
What happens if I stop taking it?
Weight regain is common if medication is stopped without a sustainable nutrition and lifestyle plan. We work with you to build habits that support long-term success.
Can I combine GLP-1 therapy with other weight loss treatments?
Yes. GLP-1 therapy is often combined with nutritional counseling, exercise programs, and other weight loss modalities for optimal results.
Is it safe?
Yes, when prescribed and monitored by a qualified medical professional. GLP-1 medications have been extensively studied and are FDA-approved for weight loss. Our medical team ensures you are carefully monitored throughout your journey.
Ready to take the first step toward sustainable weight loss?
📍 Skinovatio Ohio
1139 Rockside Rd., Parma, OH 44134
📞 216-712-4605
📧 info@skinovatioohio.com
See real results from our patients. Individual results may vary.
*Results may vary. Photos are unretouched.
Book a complimentary consultation to discuss your goals and create a personalized treatment plan.
